Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2022		Dec. 31, 2021
Assets
Investments, at fair value		$ 15,377.3	[1]	$ 16,101.5	[2]
Cash		248.0		258.0
Foreign currency, at fair value (cost—$3 and $119, respectively)		3.0		119.0
Receivable for investments sold and repaid		212.0		567.0
Income receivable		227.0		153.0
Unrealized appreciation on foreign currency forward contracts		25.0		9.0
Deferred financing costs		23.0		16.0
Prepaid expenses and other assets		9.0		5.0
Total assets		16,124.0		17,228.0
Liabilities
Payable for investments purchased		14.0		2.0
Debt (net of deferred financing costs of $34 and $38, respectively)	[3]	8,694.0		9,142.0
Unrealized depreciation on foreign currency forward contracts		1.0		1.0
Stockholder distributions payable		192.0		176.0
Management and investment adviser fees payable		59.0		60.0
Subordinated income incentive fees payable	[4]	27.0		19.0
Administrative services expense payable		6.0		5.0
Interest payable		90.0		70.0
Other accrued expenses and liabilities		29.0		23.0
Total liabilities		9,112.0		9,498.0
Commitments and contingencies	[5]
Stockholders' equity
Preferred stock, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding		0.0		0.0
Common stock, $0.001 par value, 750,000,000 shares authorized, 281,731,750 and 284,543,091 shares issued and outstanding, respectively		0.0		0.0
Capital in excess of par value		9,610.0		9,658.0
Retained earnings (accumulated deficit)	[6]	(2,598.0)		(1,928.0)
Total stockholders' equity		7,012.0		7,730.0
Total liabilities and stockholders' equity		$ 16,124.0		$ 17,228.0
Net asset per share of common stock (in dollars per share)	[6]	$ 24.89		$ 27.17
Non-controlled/unaffiliated
Assets
Investments, at fair value		$ 12,026.0		$ 12,558.0
Non-controlled/affiliated
Assets
Investments, at fair value		443.4		859.0
Controlled/affiliated
Assets
Investments, at fair value		$ 2,908.4		$ 2,684.1

[1] Fair value determined by the Company’s board of directors (see Note 8).

[2] Fair value determined by the Company’s board of directors (see Note 8).

[3] See Note 9 for a discussion of the Company’s financing arrangements.

[4] See Note 2 and 4 for a discussion of the methodology employed by the Company in calculating the subordinated income incentive fees.

[5] See Note 10 for a discussion of the Company's commitments and contingencies.

[6] See Note 5 for a discussion of the sources of distributions paid by the Company.